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ABSTRACT
Introduction. Prompt successful control of disease activity in multiple sclerosis (MS) patients improves outcomes. Therefore, 
tools to aid drug selection and detect non-responders are urgently needed. Although several biochemical markers for predict-
ing response to treatment have been proposed, clinical markers involving relapses, imaging activity and disability progression 
in the initial years of therapy remain competitive and appear cost-effective in a real-life setting. The aim of this study was to 
evaluate the prognostic value of select clinical scores in interferon beta-1b (IFNβ-1b) treated MS patients. 
Materials and methods. Eighty-eight relapsing-remitting MS (RRMS) patients initiating treatment with IFNβ-1b in a Polish 
outpatient clinic were followed for a median of 5.5 years. Rio, modified Rio and BREMSO scores, as well as two-year no evidence 
of disease activity (NEDA), were assessed as predictors of disease activity during the observation.
Results. A Rio score of 1 had a Positive Predictive Value (PPV) of 83.3% and a Negative Predictive Value (NPV) of 71.4% for the 
occurrence of relapses in the first five years. A Rio and modified Rio score of 1 was associated with MRI activity after year 3. 
A loss of NEDA within the first two years was associated with a failure to maintain NEDA in the next three years. The BREMSO 
score was higher in patients with early relapse activity. Only baseline EDSS and total number of pre-treatment relapses were 
significantly associated with disability progression.
Conclusions. Rio, modified Rio, early NEDA on treatment and BREMSO score are relatively specific, but insensitive, predictors 
of relapse activity in the first years of IFNβ-1b treatment. Higher pre-treatment EDSS and relapse activity is associated with 
disability progression, but not overall NEDA, in subsequent observation. While none of the markers is sufficiently sensitive or 
specific to make a certain prognosis, they may aid treatment decisions in patients with continued early disease activity.
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Introduction
Sustained disease activity is associated with worse short- 
and long-term outcomes in multiple sclerosis (MS) patients 
[1–3]. 
With the development of new, highly effective therapies, 
no evidence of disease activity (NEDA) has become the most 
widely accepted treatment target. Advances in pharmaco-
therapy allow us to achieve NEDA in a growing number of 
patients, although at the price of an increased risk of adverse 
effects [4, 5]. At the same time, safer but possibly less effective 
first-line agents may be sufficient to control disease activity in 
select low-risk patients. Better ways of identifying such patients 
are urgently needed.
Interferon-beta (IFNβ) continues to be widely used as 
a first-line disease modifying drug (DMD). Many prognostic 
markers for IFNβ response have been proposed, including 
clinical, imaging, biochemical and immunological parameters. 
Clinical and imaging markers have been the most studied and 
widely used. Among these, Rio score [6] and modified Rio 
score [7] have been specifically developed and validated for 
IFNβ-treated patients. These scores allow for some disease ac-
tivity in the responder group. On the other hand, maintenance 
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of NEDA in the first two years of therapy has recently been 
suggested as a predictive marker and found to correlate with 
a lack of disability progression of up to seven years [8].
Another approach towards computing a prognostic score, 
the Bayesian Risk Estimate for MS (BREMS), comprises age, 
gender, initial relapse characteristics (motor, motor-sensory 
and/or sphincter involvement, number of functional systems 
affected, completeness of recovery), and events within the 
first year from disease onset (motor and sphincter relapse, 
reaching EDSS 4) [9]. BREMS was specifically developed to 
evaluate the risk of an unfavourable natural history of the 
disease. The BREMS score is significantly higher in untreated 
patients reaching secondary progressive MS within 10 years 
[9, 10]. A simplified score omitting the first year’s observation, 
namely BREMSO [10], has been shown to highly correlate to 
BREMS and to predict disease progression.
The aim of our study was to assess the value of scores al-
lowing for minimal disease activity (Rio and modified Rio), 
a restrictive no-activity score (two-year NEDA), or a composite 
pre-treatment risk estimate (BREMSO), as predictive factors 
for treatment response in a Polish population of IFNβ-1b 
treated RRMS patients.
Materials and methods
The study protocol was approved by the Internal Review 
Ethics Board of Poznan University of Medical Sciences. All 
patients gave written informed consent for study participation. 
Study group
Eighty-eight treatment-naïve, adult, relapsing-remitting 
MS patients were recruited consecutively between 2008 and 
2013 while initiated on IFNβ-1b treatment in the MS outpatient 
clinic by Heliodor Swiecicki University Hospital in Poznan, 
Poland. All patients met the revised 2010 McDonald criteria for 
the diagnosis of RRMS [11]. The patients were treated within 
the setting of the Polish National Health Fund MS treatment 
programme, with eligibility criteria as outlined in Table 1. 
Treatment
Each patient received 8 MIU (250μg) of IFNβ-1b (Betafer-
on, Bayer in 83 patients; or Extavia, Novartis in five patients) 
subcutaneously every other day.
Follow-up
Each patient was assessed monthly by a neurologist who 
recorded relapses and EDSS score changes.
A 1.5 Tesla brain magnetic resonance imaging (MRI, 
Siemens Avanto, Erlangen, Germany) with a 12-channel head 
coil, including T1, T2, Fluid Attenuated Inversion Recovery 
(FLAIR) and Proton Density (PD) sequences, with gadolinium 
contrast administration, was performed at baseline and repe-
ated yearly. Spinal MRI was obtained when deemed necessary 
by the treating physician.
For each subsequent year, the number of relapses, active 
lesions on MRI, and change in EDSS were recorded, and NEDA 
status was determined for each subject.
Scoring
Rio score is calculated as described by Rio et al. [6], as the sum 
of the following three criteria assessed after the first year of therapy:
 — MRI criterion = 1; if > 2 active MRI lesions (new or enlarging 
T2-weighted lesions, + the number of gadolinium-enhanc-
ing (Gd+) T1-weighted lesions on the yearly MRI scan); 
 — relapse criterion = 1; if ≥ 1 relapse; 
 — EDSS criterion = 1; if an increase in EDSS score of 
≥ 1 point, sustained ≥ 6 months and confirmed at the end 
of the follow-up period.
Modified Rio score [7] includes two criteria, scored after 
the first year of treatment:
 — MRI criterion = 1, if > 4 new T2 lesions;
 — relapse criterion = 1 if 1 relapse occurred; = 2 if ≥ 2 re-
lapses.
BREMSO score was computed as described previously 
[10], using the formula:
 — 0.05 × age (in decades)
 — –1.07 (if female gender)
 — +0.93 (if sphincter onset)
 — +0.62 (if pure motor onset)
 — +0.81 (if motor and sensory onset)
 — +0.32 × number of neurological functional systems invol-
ved at onset
 — +0.52 (if incomplete recovery after onset)
No evidence of disease activity (NEDA) was defined as it has 
been previously [12]: within a given time window, NEDA means 
no relapses, no disability progression, and no MRI activity. 
A relapse was defined as the emergence or worsening of 
symptoms applicable to multiple sclerosis, with focal neurolo-
gical abnormality lasting 24 hours and preceded by ≥ 30 days of 
stable neurological status, in the absence of fever or infection. 
Disability progression was scored after an increase in EDSS 
confirmed after 3 months: ≥ 1.5 for a baseline score of 0; 
≥ 1.0 for scores from 1.0 to 5.0; and ≥ 0.5 for baseline score 
of ≥ 5.5. MRI activity was defined as new or enlarging lesions 
on T2/FLAIR or any contrast enhancing lesions.
Statistical analysis
P values of ≤ 0.05 were considered statistically significant.
Variables were tested for normality of distribution and 
equality of variances with d’Agostino-Pearson’s and Levene’s 
tests. They were reported as means ± standard deviations (SD) 
when normally distributed, or medians with interquartile 
ranges (IQR) otherwise.
Baseline characteristics were assessed for mutual correla-
tions and compared to Rio, modified Rio, and BREMSO scores.
Associations were calculated between scale scores 
and outcomes (i.e. NEDA, relapse occurrence, disability 
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Table 1. Eligibility criteria for Polish National Health Fund MS treatment programme 2008–2013
Criterion Before 2012 Since 2012
Diagnosis RRMS according to 2005 McDonald criteria AND contrast-enhanced head MRI consistent with MS
Disease activity ≥ 2 relapses within last two years No criteria
Required score ≥ 21 points ≥ 15 points
Scoring system Age (years):
16–40 = 6 pts
40–60 = 3 pts
> 60 = 1 pt
Disease duration (years):
 0–3 = 6 pts
3–6 = 3 pts
6–10 = 2 pts
> 10 = 1 pt
No neurological deficit = 5 pts
Number of relapses in the last year:
3–4 = 5 pts
1–2 = 4 pts
6–7 = 2 pts
none (less than 1/year) = 1 pt
>7 = 0 pts
EDSS score:
0–2 = 6 pts
2.5–4 = 3 pts
4.5–5 = 2 pts
> 5 = 1 pt 
Disease duration (years):
 0–3 = 6 pts
3–6 = 4 pts
6–10 = 2 pts
> 10 = 1 pt
No neurological deficit = 5 pts
Number of relapses in the last year:
≥ 3 = 5 pts
1–2 = 4 pts
none = 1pt
EDSS score:
0–2 = 6 pts
2.5–4 = 5 pts
4.5–5 = 2 pts
> 5 = 1 pt 
Exclusion criteria 1. allergy to IFNβ
2. primarily or secondarily progressive MS
3. pregnancy
4. uncontrolled liver disease (aminotranferase levels ≥ 2 × upper reference limit)
5. uncontrolled thyroid disease (no euthyreosis)
6. a history of: 
1. intractable depressive mood disorder or suicidal ideation;
2. epilepsy.
MS — multiple sclerosis; RRMS — relapsing-remitting multiple sclerosis; MRI — magnetic resonance imaging; EDSS — Expanded Disability Status Score; pt — point
progression, MRI activity) in each subsequent year, for each 
period up to a subsequent year, after each subsequent year, 
and for the entire follow-up. The first year was excluded 
from correlations with first-year NEDA, Rio and modified 
Rio scores. Likewise the first two years were not considered 
for the correlations with second-year and two-year NEDA 
status or MRI activity. 
The follow-up results were also assessed for correlations 
with other baseline characteristics.
Fisher’s exact test was used for nominal and Mann-
-Whitney U test for ordinal variables. For interval variab-
les, either a t-test or Mann-Whitney U test was employed, 
depending on the normality of distribution. For significant 
associations, sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV) were determi-
ned. Receiver operating characteristic (ROC) curves were 
generated and areas under the curve (AUC) calculated for 
BREMSO. 
Statistical analyses were performed using StatSoft STATI-
STICA version 13 [13] and MedCalc, version 15.8 [14].
Results
Patient characteristics, including demographics 
and treatment response 
Eighty-eight patients (67 females, 21 males) were recruited 
for the study. Mean age at first relapse was 30.0 ± 9.1 years. 
It was higher in females (31.3 ± 9.6) than males (25.9 ± 5.3) 
(p = 0.002). There was no significant gender-specific difference 
in time to second relapse, time to treatment initiation, number 
of relapses before treatment, EDSS at baseline, or follow-up 
duration. Median delay from the first relapse to treatment 
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onset was 18 months, and the median EDSS at treatment start 
was 1.0 (ranging from 0 to 4, IQR 0–1.0).
BREMSO scoring was possible in 80 patients, Rio score was 
obtainable in 50, and modified Rio in 50. Overall, 49 patients 
had both Rio and modified Rio, while 42 patients had all three 
scores. There was no statistically significant difference between 
these groups in baseline clinical features, including gender, 
age at first relapse, time to second relapse, time to treatment 
initiation, EDSS score, or relapses prior to treatment initiation.
The cohort was followed for a median of 5.5 years (range 
0.4 to 9.2). Each year, between 60% and 80% of the patient 
cohort achieved NEDA (Fig. 1). In the first two years, relapses 
were the most common form of activity. Later, MRI activity 
predominated. In subsequent years, a cumulative loss of NEDA 
was observed.
During the follow-up, treatment was stopped in 51 patients. 
Until 2012, the Polish IFN treatment programme was limited to 
three years, and this was the sole reason for discontinuation in 
14 cases (27%). Five patients (10%) either planned pregnancy 
or became pregnant. Thirteen patients switched DMD due to 
adverse effects (25%), and in 14 (27%) IFNβ-1b was deemed to 
be ineffective. Five patients (10%) resigned for other reasons.
Among baseline clinical characteristics, in stepwise 
logistic regression, only pre-treatment EDSS score and 
total pre-treatment relapses were consistently correlated 
with outcome: higher EDSS scores were robustly associated 
with further disability progression in up to eight years of 
observation and NEDA loss in the first three years, while the 
number of relapses correlated with disability progression in 
the first six years. Considering the presence or absence of 
progression in the entire follow-up (regardless of its length), 
a significant association was found with both baseline EDSS 
and pre-treatment relapses.
A summary of the associations of the different scoring 
methods with disease activity during follow-up is presented 
in Table 2.
Rio and modified Rio score over the first year of 
IFNβ-1b treatment
Thirty-nine (78%) patients had a Rio score of 0, ten (20%) 
had a score of 1, and one case (2%) was graded 2. Forty-one 
(82%) patients had a modified Rio score of 0, eight (16%) had 
a score of 1, and one case (2%) was graded 2. In our cohort, Rio 
and modified Rio score were strongly correlated (p < 0.00001; 
Rio and modified Rio score was different in three cases only).
There was no significant association between either Rio 
or modified Rio score and baseline clinical features, including 
pre-treatment EDSS and total number of relapses, age at first 
relapse, time to second relapse, or time to treatment onset.
Patients with scores > 0 in the Rio scale were more likely 
to experience relapses up to the first 4-5 years of treatment. 
For modified Rio, a similar trend for the first four years was 
noted, but failed to reach statistical significance (p = 0.066). 
No association with disability progression was present.
BREMSO
In the entire cohort, mean BREMSO score was 0.213 
± 0.779 (median 0.350 with IQR –0.600 to 0.680). As expected, 
it was significantly higher in males (median 0.940, IQR 0.420 to 
1.350) than females (median –0.055; IQR -0.650 to 0.530; 
p < 0.00001). It was also weakly correlated with pre-treatment 
EDSS score (Kendall tau = 0.211; p = 0.049). 
BREMSO score was higher in patients with disease activity 
in the first year of treatment (p = 0.035). It was also higher 
in patients with relapses in the first 2-3 years of treatment 
(p = 0.048 and 0.016, respectively).
Exact values are shown in Table 3 (supplementary ma-
terials). 
In ROC analysis, the criterion > 0.58 had the highest com-
bined sensitivity and specificity for both loss of NEDA in the 
first year and the occurrence of relapses within the first two 
or three years of treatment.
Two-year NEDA
Patients failing to maintain NEDA during the first two 
years of therapy were more likely to experience disease activ-
ity within the following 2-3 years, i.e. in years 3 to 4 and 3 to 
5 of the follow-up. They were also more likely to have relapses 
in years 3 to 4. 
As the effect of IFNβ-1b may not be apparent in the first 
six months of treatment, we also considered the prognostic 
value of NEDA in the second year alone. NEDA in year 2 con-
ferred a significantly lower risk of relapses in year 3. No other 
statistically significant correlation with later disease course 
was observed. However, there was a trend (p = 0.055) towards 
a lower risk of disability progression within the next four years 
(years 3 to 6 of the follow-up).
Meanwhile, a loss of NEDA during the first year correlated 
with higher risks of relapses and NEDA loss in years 2–4.
Discussion
To the best of our knowledge, this is the first study to have 
assessed the utility of Rio, NEDA and BREMSO as prognostic 
factors in a Polish population of IFNβ-treated MS patients. 
Previously assessed were the baseline clinical features [15]: 
higher pre-treatment EDSS as well as higher annualised 
relapse ratio were associated with poor response at two and 
three years, respectively. 
Our observations confirm and extend this observation, as 
higher pre-treatment EDSS and total number of relapses were 
associated with disability progression in our cohort, indepen-
dently of other predictive factors. In fact, high baseline EDSS and 
early relapse activity have been consistently reported as the main 
negative prognostic factors in MS patients on DMDs [16–19].
In our cohort, Rio, early NEDA and BREMSO score were 
relatively specific, but insensitive, predictors of relapse activity 
in the first years of IFNβ-1b treatment. First two years NEDA 
and BREMSO also correlate with short-term NEDA.
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Case Year Case Year
Neda Loss of NEDA Relapse(s) Disability progression MRI activity
Figure 1. Disease activity, including NEDA status, relapse activity, disability progression and MRI activity, in the study cohort. Subsequent 
lines represent individual cases
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In the original report [6], a Rio score ≥ 2 after one year of 
treatment predicted the occurrence of relapses or disability 
progression over two subsequent years, i.e. in years 2–3. While 
a score of 1 was associated with an odds ratio of 1.4 for disease 
activity, it did not reach statistical significance. Modified Rio 
score was developed as a simplified but equally effective predic-
tive marker [7]. A score ≥ 2 identified non-responders, defined 
as patients with disability progression or > 1 relapse, with PPV 
= 83% and NPV of 68%. An analysis of the ≥ 2 threshold was 
not possible in our study. Our cohort experienced a relatively 
mild first year of treatment, and so only a single patient scored 
2 in Rio and another in modified Rio. 
Nevertheless, the extended follow-up in our study revealed 
that even a Rio score ≥ 1 confers an increased risk of disease 
activity, namely relapse occurrence in years 2–4. Meanwhile, 
the modified Rio score, omitting disability progression and al-
lowing for more MRI activity, failed to predict disease activity 
in our patients. Neither Rio nor modified Rio correlated with 
disability progression.
A recent review [3] found that after the first year of treat-
ment, alongside Rio score, the appearance of new T2 lesions 
has the highest predictive value for disability progression in 
subsequent years. In IFN-treated patients, new or enhancing 
lesions at first-year MRI scan were predictive of disability 
worsening both at short-term (two years, [20, 21], five years 
[22]) and in long-term observation (15–16 years, [2, 23]). These 
observations contrast with the work of Goodin et al. [24], 
who found that no relapses and no EDSS worsening (‘clinical 
NEDA’) was just as good a predictor of future positive outcome 
as full NEDA, including lack of MRI activity. Our study was not 
designed to address the utility of MRI as a prognostic factor.
In our cohort, NEDA in the first two years had PPV of 50% 
and NPV of 79.2% for maintaining NEDA in years 3–5. Loss 
of NEDA in first two years was associated with increased risk 
of relapses in years 2–4. 
On the other hand, we observed no correlation of NEDA 
status with disability progression. This may be caused by 
the adherence to NEDA-derived definition of disability 
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Table 3. Statistically significant differences in BREMSO between patients with and without disease activity
Comparison Non-active Active p
N Mean ± SD or median (IQR) N Mean ± SD or median (IQR)
BREMSO vs NEDA
in year 1 61 0.110 ± 0.754 < 19 0.540 ± 0.786 0.035
BREMSO vs relapses
until year 2 59 0.123 ± 0.736 < 20 0.519 ± 0.842 0.048
until year 3 48 0.045 (-0.600 to 0.475) < 25 0.680 (-0.600 to 1.102) 0.016
BREMSO vs progression
in year 5 44 0.02 (-0.650 to 0.480) < 3 0.540 (0.533 to 0.923) 0.044
BREMSO vs MRI
in year 5 42 -0.13 (-0.650 to 0.480) < 4 0.735 (0.530 to 1.170) 0.014
N — number of cases; SD — standard deviation; IQR — interquartile range
progression. Arguably, outcome definitions have a large im-
pact on conclusions drawn from observational studies. The 
maintenance of NEDA for the first two years of treatment was 
found to predict no disability progression, defined as no EDSS 
worsening of ≥ 0.5 after seven years of follow-up in a mixed-
treatment group [8]. In the randomised IFNβ-1b trial, loss of 
NEDA status in the first two years predicted a poor outcome 
at 16 years, defined as progressive MS, the requirement for 
a wheelchair, or EDSS ≥ 6 [24]. In addition, maintaining 
NEDA was associated with higher survival rates at 21 years. 
These results underline the significance of early successful 
disease control for very long-term outcome measures.
While Rio and modified Rio scales are easy to calculate, 
and the concept of NEDA is uncomplicated, BREMSO score 
is a relatively complex Bayesian statistical model [10]. Even so, 
we decided to include it because unlike the aforementioned 
predictors, it does not require a treatment trial, potentially 
sparing the patient one or two years of ineffective therapy. As 
observational studies have consistently shown that a higher 
number of relapses in the first 2–5 years leads to faster dis-
ability accumulation and a higher probability of reaching 
secondary progression [17–19, 25], we believe that the use of 
more sophisticated predictive tools is well justified.
In our study, BREMSO pre-treatment score of > 0.58 was 
moderately specific at predicting relapses in the first three years 
of therapy. It was also associated with loss of NEDA in the first 
year of treatment, but not in the subsequent observation. While 
BREMSO has been indicated as a prognostic marker in MS 
natural evolution [10], associations with disease progression 
were scant in our IFNβ-treated cohort. BREMSO score was 
higher in patients with progression in the 5th year (p = 0.044), 
but the active group contained only three cases. BREMSO cor-
related marginally better with the final EDSS score (Kendall 
tau = 0.248; p = 0.021) than with pre-treatment EDSS.
Our study has several limitations. Complete follow-up 
data was not available in many patients: notably, a first-year 
MRI was performed in only half of the original cohort (for 
organisational and reimbursement reasons). Limited access 
to diagnostics and therapeutic programmes at the time of 
recruitment also explains the considerable (18 month) delay 
from the first relapse to treatment initiation. Numerous cases 
discontinued treatment throughout the study, lowering the 
statistical power in subsequent years of observation.
Overall, our results suggest that in IFNβ-1b treated RRMS 
patients, any disease activity within the first two years of 
therapy (defined as loss of NEDA or ≥ 1 point in Rio score) is 
associated with disease activity in the subsequent two or three 
years, predominately in the form of relapses. 
For the prediction of relapses, compared to Rio score 
NEDA is slightly more sensitive, but this comes with a marked 
cost in specificity. BREMSO, as a pre-treatment assessment 
score, should therefore offer an advantage over Rio, because 
its associations with relapse activity were comparably specific 
and more sensitive, although they were limited to the first three 
years of treatment. For loss of NEDA, only early NEDA (in the 
first one or two years) appears to have any predictive value: 
the utility of BREMSO does not extend beyond the first year, 
possibly reflecting activity before IFN action onset as opposed 
to drug response. Rio score was not associated with NEDA or 
its components except for relapses.
In conclusion, none of the analysed factors is sensitive or 
specific enough to reliably classify patients as responders or 
non-responders. Disease activity prompting DMD change is 
associated with a loss of the early window of therapeutic op-
portunity in MS. In fact, it was recently shown that escalation 
strategies in real-world settings translate into faster disability 
progression than initial high-efficiency treatment [26]. Usually 
the progression had already occurred by the time DMD was 
switched, a clear indication that the decision was made too late.
Furthermore, with observational study design it is im-
possible to determine whether DMD switch would have any 
impact on the outcome, i.e. whether it was the severity of 
disease or poor drug activity that was to blame for the poor 
response.
Keeping the above in mind, we believe that further research 
should focus on:
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1) pre-treatment and on-treatment predictors of sustained 
good response that allow for the identification of patients 
in whom a low-potency DMD is likely to suffice;
2) pre-treatment predictors of poor response: here, a study 
design should target a benefit from treatment modification, 
rather than just a poor response to a given DMD.
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